ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 216

Does Fibromyalgia Change the Evaluation of Spondyloarthritis Activity? A Meta-analysis of Observational Studies

Arthur Beck1, Lilian SOLE 1, Thomas Barnetche 2 and Pascale Vergne-Salle 1, 1CHU de LIMOGES, LIMOGES, France, 2CHU de BORDEAUX, BORDEAUX, France

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: fibromyalgia, spondylarthritis and spondylarthropathy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Fibromyalgia & Other Clinical Pain Syndromes Poster

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Recent studies evaluated the prevalence of Fibromyalgia (FM) in Spondyloarthritis (SpA) and its impact on disease activity scores, but none meta-analysis exists yet. Therefore, we performed a meta-analysis to evaluate the impact of fibromyalgia on activity scores in SpA.

Methods: We performed a systematic review of the literature until May 2019 using database including: MEDLINE (via PUBMED), EMBASE and abstracts from the ACR and EULAR congresses 2016-2019. We selected observational studies comparing characteristics of SpA patients (defined by ASAS, NY modified or CASPAR criteria) with or without fibromyalgia (defined by ACR 1990, 2011 fibromyalgia criteria or FiRST survey).

Two readers extracted the prevalence of FM in SpA, female ratio, HLAB27 status, disease duration, radiographic sacroiliitis, C-reactive protein (CRP), BASDAI, BASFI, ASDAS-CRP and Quality of Life (QoL).

Statistical analysis determined in each study theeffect size. Data was analyzed using the inverse variance approach.

Results: The literature search identified 433 articles. Finally, 15 studies met the inclusion criteria.

The prevalence of FM in SpA was 17% IC95% [0.12, 0.23] with a significant female ratio of 5.13 IC95%[3.02, 8.70]in SpA with FM.

FM impacted significantly all the activity scores of SpA: BASDAI: OR= 2.18 IC95%[1.45, 2.91]; BASFI: OR= 2.33 IC95%[1.65, 3.02]; ASDAS-CRP: OR= 0.54 IC95%[0.05, 1.02]; AsQoL: OR=5.50 IC95%[4.28, 6.71]

No statistical difference was found concerning HLAB27 status, disease duration and CRP level.

Conclusion: In this meta-analysis, the prevalence of FM in SpA was 17%, whereas 2-8% in general population. The coexistence of FM with SpA led to higher activity scores, including ASDAS-CRP, although CRP trends to be lower in the FM group.

Rheumatologist have to be aware of the association of FM and SpA, activity scores may be biased.

BASDAI

BASFI

ASDAS-CRP


Disclosure: A. Beck, None; L. SOLE, None; T. Barnetche, None; P. Vergne-Salle, None.

To cite this abstract in AMA style:

Beck A, SOLE L, Barnetche T, Vergne-Salle P. Does Fibromyalgia Change the Evaluation of Spondyloarthritis Activity? A Meta-analysis of Observational Studies [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/does-fibromyalgia-change-the-evaluation-of-spondyloarthritis-activity-a-meta-analysis-of-observational-studies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/does-fibromyalgia-change-the-evaluation-of-spondyloarthritis-activity-a-meta-analysis-of-observational-studies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology